跳至主要内容
临床试验/NCT07397585
NCT07397585招募中不适用

stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database

Istituto Clinico Humanitas28 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2025年2月25日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
300
试验地点
28
主要终点
progression free survival

研究概览

简要总结

Oligometastatic breast cancer is a condition in which breast cancer has spread to a small number of other parts of the body. Patients with this type of disease may live longer than those with more widespread metastases. In addition to standard treatments that act on the whole body, such as chemotherapy or hormonal therapy, these patients might also benefit from local treatments that directly target the cancer spots. One of these local treatments is stereotactic body radiotherapy (SBRT), a non-invasive radiation treatment that delivers high doses of radiation in a few sessions. In the past, most of the evidence about the benefit of local treatments came from surgery. More recently, there has been growing interest in SBRT because it does not require surgery. However, the results of studies so far have not been consistent.The goal of this multicenter retrospective study is to better understand whether SBRT can improve disease control and survival in patients with breast cancer that has spread to a limited number of sites outside the brain.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients ≥18 years
  • Histological diagnosis of breast cancer
  • Oligometastatic or oligoprogressive metastatic breast cancer
  • SBRT delivered to a minimum dose of 50Gy EQD2 (αβ 10 Gy),in a maximum of 12 fractions as per Oligocare definition
  • Ability to provide written informed consent

排除标准

  • 未提供

研究组 & 干预措施

TREATMENT SBRT

patients who have been treated with stereotactic radiotherapy to oligometastatic sites

结局指标

主要结局

progression free survival

时间窗: from January 2010 to December 2023

years of survival without disease progression assessed by imaging

次要结局

  • Local Control(from January 2010 to December 2023)
  • overall survival(From January 2010 to December 2023)
  • acute and late toxicity RT related(from January 2010 to December 2023)

研究者

发起方
Istituto Clinico Humanitas
申办方类型
Other
责任方
Sponsor

研究点 (28)

Loading locations...

相似试验